TY - JOUR
T1 - Genetic/familial high-risk assessment
T2 - Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines
AU - Daly, Mary B.
AU - Pilarski, Robert
AU - Yurgelun, Matthew B.
AU - Berry, Michael P.
AU - Buys, Saundra S.
AU - Dickson, Patricia
AU - Domchek, Susan M.
AU - Elkhanany, Ahmed
AU - Friedman, Susan
AU - Garber, Judy E.
AU - Goggins, Michael
AU - Hutton, Mollie L.
AU - Khan, Seema
AU - Klein, Catherine
AU - Kohlmann, Wendy
AU - Kurian, Allison W.
AU - Laronga, Christine
AU - Litton, Jennifer K.
AU - Mak, Julie S.
AU - Menendez, Carolyn S.
AU - Merajver, Sofia D.
AU - Norquist, Barbara S.
AU - Offit, Kenneth
AU - Pal, Tuya
AU - Pederson, Holly J.
AU - Reiser, Gwen
AU - Shannon, Kristen Mahoney
AU - Visvanathan, Kala
AU - Weitzel, Jeffrey N.
AU - Wick, Myra J.
AU - Wisinski, Kari B.
AU - Dwyer, Mary A.
AU - Darlow, Susan D.
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
PY - 2020/4
Y1 - 2020/4
N2 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
AB - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
UR - https://www.scopus.com/pages/publications/85083022514
U2 - 10.6004/jnccn.2020.0017
DO - 10.6004/jnccn.2020.0017
M3 - Article
C2 - 32259785
AN - SCOPUS:85083022514
SN - 1540-1405
VL - 18
SP - 380
EP - 391
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 4
ER -